{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yin MT"],"funding":["NCATS NIH HHS","NIAID NIH HHS","NHLBI NIH HHS","NIMH NIH HHS"],"pagination":["1683-1688"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9444941"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(12)"],"pubmed_abstract":["<h4>Background</h4>Fracture rates have been reported to be higher among older women living with HIV (WLWH) than HIV- women. Hormone therapy with estrogen can reduce vasomotor symptoms (VMS) associated with menopause and prevent fractures. As data are limited on the benefits of hormone therapy use in WLWH, we examined associations of hormone therapy, use and fractures.<h4>Methods</h4>A prospective study of 1765 (1350 WLWH and 415 HIV-) postmenopausal Women's Interagency HIV Study (WIHS) participants was performed, including self-reported hormone therapy, use and fracture data from 2003 to 2017. Proportional hazard models determined predictors of new fractures at any site or at typical fragility fracture sites (hip, spine, wrist).<h4>Results</h4>At the first postmenopausal visit, the median "],"journal":["AIDS (London, England)"],"pubmed_title":["Hormone therapy and fractures in postmenopausal women."],"pmcid":["PMC9444941"],"funding_grant_id":["P30 AI050410","UL1 TR001881","U01 HL146205","U01 HL146204","U01 HL146203","U01 HL146208","U01 HL146242","U01 HL146241","U01 HL146240","U01 HL146202","U01 HL146201","U01 HL146245","K24 AI155230","P30 MH116867","P30 AI073961","P30 AI027767","UL1 TR003098","U01 AI069470","U01 AI031834","R01 AI095089","UL1 TR000004","P30 AI050409","U01 HL146333","UM1 AI069470","U01 HL146194","U01 HL146193","U01 HL146192"],"pubmed_authors":["Bares SH","Bolivar H","Hoover DR","Shi Q","Warriner A","Cohen MH","Adimora A","Tien PC","Yin MT","Sharma A","Weitzmann MN","Gustafson D","Kassaye S"],"additional_accession":[]},"is_claimable":false,"name":"Hormone therapy and fractures in postmenopausal women.","description":"<h4>Background</h4>Fracture rates have been reported to be higher among older women living with HIV (WLWH) than HIV- women. Hormone therapy with estrogen can reduce vasomotor symptoms (VMS) associated with menopause and prevent fractures. As data are limited on the benefits of hormone therapy use in WLWH, we examined associations of hormone therapy, use and fractures.<h4>Methods</h4>A prospective study of 1765 (1350 WLWH and 415 HIV-) postmenopausal Women's Interagency HIV Study (WIHS) participants was performed, including self-reported hormone therapy, use and fracture data from 2003 to 2017. Proportional hazard models determined predictors of new fractures at any site or at typical fragility fracture sites (hip, spine, wrist).<h4>Results</h4>At the first postmenopausal visit, the median ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-05T09:43:03.564Z","creation":"2025-04-05T09:43:03.564Z"},"accession":"S-EPMC9444941","cross_references":{"pubmed":["35730385"],"doi":["10.1097/QAD.0000000000003292","10.1097/qad.0000000000003292"]}}